Videos from the Webinar with Dr. Serge Verstovsek on the Future of MPN Treatment
- Peter Löffelhardt
- Jun 25
- 2 min read
📅 Originally aired: May 29, 2025
🎙 Hosted by the Global MPN Scientific Foundation
🧪 Featuring: Dr. Serge Verstovsek, world-leading MPN researcher
The Global MPN Scientific Foundation, in collaboration with Kartos Therapeutics, recently hosted an exclusive webinar with Dr. Serge Verstovsek, offering a unique window into the POIESIS clinical trial and the future of Myeloproliferative Neoplasm (MPN) treatment.
Dr. Verstovsek shared cutting-edge updates on the development of Navtemadlin, a promising new therapy for Myelofibrosis, and answered key questions from the community about clinical research and access to innovative treatments.
This session provided invaluable information for both patients and professionals seeking to stay informed about the latest in MPN care.
Content Guide
PART 1 – A New Era: Navtemadlin and the Therapeutic Approach
Dr. Verstovsek introduced Navtemadlin, a new oral therapy designed to restore P53 activity and drive cancer cell death selectively. This section explained how the drug works, its targeted action in MPNs, and the biological rationale behind its use.
Want to watch Parts 2 and 3?
🧬 Are you a patient or caregiver? Join our community at MPN World to access the full webinar and connect with others like you.
🩺 Are you a physician or healthcare professional? Write to us at info@gmpnsf.org to request access and learn more about the ongoing clinical developments in MPN care.
Why this matters
Clinical research is moving fast. POIESIS represents a step forward in developing treatments that go beyond symptom control, aiming for disease modification and better quality of life.
At the Global MPN Scientific Foundation, we believe in providing access to trustworthy, expert-led information. Sessions like this empower the community and build a bridge between science and real-life experience.
Together, we move forward.
Comments